PARK CITY, Utah--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in implantable Tibial Neuromodulation (iTNM) and developer of the Revi® System, a patient-centric solution for urge urinary ...
A 41-year-old nurse from Severance shopping for a solution to her overactive bladder symptoms found a way to regain full control thanks to an innovative procedure. Sarah Avrech said goodbye to a life ...
(HealthDay News) — For women with refractory urgency urinary incontinence, onabotulinumtoxinA injections may help control leakage better than the implanted nerve stimulation device InterStim, ...
Fewer punctures and shorter surgical time reported for sacral neuromodulation with 3D printing and ultrasound localization. (HealthDay News) — For patients with neurogenic bladder and pelvic ...
Kathy Boehm shows where the charger is placed to recharge her implant. The charger can be in a belt or tucked inside her pants. Dr. Tarek Garas Dr. Lindsey Hahn Locating the nearest bathroom when she ...
The US Food and Drug Administration (FDA) has approved Neuspera Medical’s integrated sacral neuromodulation (iSNM) system for treating urinary urge incontinence (UUI). The California-based company’s ...
Sacral neuromodulation, which is also called interstim, acts to provide a small amount of electrical stimulation to the nerves that run through the tailbone (sacrum) to the bladder. For reasons we do ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...
Please provide your email address to receive an email when new articles are posted on . According to a company release, the R20 neurostimulator has been labeled for a functional life span of at least ...
SAN JOSE, Calif., June 18, 2025 /PRNewswire/ -- Neuspera ® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced that the U.S. Food ...
DUBLIN, March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the first patient implants in the TITAN 2 pivotal study that will evaluate ...